Cite

HARVARD Citation

    Kefalas, P. et al. (2018). Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy. Journal of market access & health policy. 6 (1), p. . [Online]. 
  
Back to record